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Abstract:	
Significant	 age	 and	 experience-dependent	 remodelling	 of	 spinal	 and	 supraspinal	 neural	 networks	
occur	 resulting	 in	 altered	 pain	 responses	 in	 early	 life.	 In	 adults	 endogenous	 opioid	 peptide	 and	
endocannabinoid	(ECs)	pain	control	systems	exist	which	modify	pain	responses	but	the	role	they	play	
in	acute	responses	to	pain	and	postnatal	neurodevelopment	is	unknown.	Here	we	have	studied	the	
changing	 role	of	 the	ECs	 in	brainstem	nuclei	 essential	 for	 the	 control	of	nociception	 from	birth	 to	
adulthood	in	both	rat	and	human.	Using	in	vivo	electrophysiology	we	show	that	substantial	functional	
changes	 occur	 in	 the	 effect	 of	 microinjection	 of	 ECs	 receptor	 agonists	 and	 antagonists	 in	 the	
periaqueductal	grey	(PAG)	and	rostroventral	medulla	(RVM),	both	of	which	play	central	roles	in	the	
supraspinal	control	of	pain	and	the	maintenance	of	chronic	pain	states	in	adulthood.	We	show	that	in	
immature	PAG	and	RVM	the	orphan	receptor	GPR55	is	able	to	mediate	profound	analgesia	which	is	
absent	in	adults.	We	show	that	tissue	levels	of	endocannabinoid	neurotransmitters,	anandamide	and	
2-arachidonoylglycerol	 within	 the	 PAG	 and	 RVM	 are	 developmentally	 regulated	 (using	 mass	
spectrometry).	The	expression	patterns	and	levels	of	ECs	enzymes	and	receptors	were	assessed	using	
quantitative	PCR	and	immunohistochemistry.	In	human	brainstem	we	show	age-related	alterations	in	
the	 expression	 of	 key	 enzymes	 and	 receptors	 in	 involved	 in	 ECs	 function	 using	 PCR	 and	 in	 situ	
hybridisation.	These	data	reveal	significant	changes	on	ECs	that	to	this	point	have	been	unknown	and	
which	shed	new	light	into	the	complex	neurochemical	changes	that	permit	normal,	mature	responses	
to	pain.	
	
Introduction	
Pain	 in	 infancy	 is	a	clinical	concern	and	has	been	recognised	as	being	sub-optimally	managed	[60].	
Previous	 studies	 have	 shown	 that	 pain	 processing	 in	 young	 mammals	 is	 immature:	 nocifensive	
withdrawal	thresholds	are	lower,	and	response	magnitudes	are	greater	and	longer	lasting	during	early	
life	 [22].	Normal	 adult	 processing	 of	 noxious	 sensory	 inputs	 requires	 a	 constant	 balance	 between	
synaptic	excitation	and	inhibition	within	the	somatosensory	pathway	[17;	58].	Descending	modulatory	
pathways,	specifically	the	spino-bulbo-spinal	 loop,	plays	a	key	role	in	modulating	spinally	mediated	
nociceptive	 reflexes	 [49].	 The	 periaqueductal	 grey	 (PAG)	 of	 the	 midbrain	 and	 nuclei	 within	 the	
rostroventral	medial	medulla	(RVM)	are	pivotal	within	this	loop	[19;	32;	39;	40;	43],	as	they	integrate	
pain-related	activity	from	forebrain	structures	and	bi-directionally	modulate	spinal	cord	dorsal	horn	
(DH)	excitability	accordingly	[19].		Functional	nociceptive	processing	requires	a	prolonged	period	of	
postnatal	maturation	and	 immature	pain	behaviours	 are	partly	 explained	by	 the	predominance	of	
synaptic	excitation	over	inhibition	within	the	DH	[1;	21;	23;	28;	30;	38;	39;	54].		Opioidergic	activity	
within	 the	 descending	 pathway	 is	 one	 of	 the	 major	 neurotransmitter	 systems	 responsible	 for	
endogenous	pain	control	 [2-4]	and	we	and	others	have	previously	shown	that	significant	postnatal	
refinement	occur	in	the	opioidergic	signalling	system	[30;	39].		
Alongside	the	opioidergic	pain	modulatory	system,	a	parallel	endocannabinoid	(EC)	signalling	system	
exists	[13;	41;	62].	In	adult	rodents,	the	administration	of	synthetic	cannabinoid	agonists	into	the	PAG	
are	antinociceptive	 [20;	34;	41],	 and	 this	 effect	 is	 known	 to	be	mediated	via	 the	CB1	 cannabinoid	
receptor	[13].	The	other	cannabinoid	receptor,	CB2,	is	mainly	expressed	by	peripheral	immune	cells	
[50].	However,	CB2	receptor	is	also	expressed	by	neurons	and	glial	cells	within	the	brainstem	and	DH,	
and	 upon	 activation	 alleviates	 inflammatory	 pain	 hypersensitivity	 [15]	 [26].	 Additionally,	 a	 non-
classical	cannabinoid	receptor,	GPR55,	 is	expressed	by	both	neuronal	and	glial	cells	within	the	CNS	
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[46].	The	study	of	GPR55-mediated	pain	modulation	is	still	in	its	infancy	[25;	53;	56]	and	roles	in	both	
pro-	and	anti-nociception	upon	receptor	activation	were	observed	[53].		
It	is	widely	accepted	that	apart	from	pain	modulation,	the	EC	signalling	system	serves	a	trophic	role	in	
utero,	 guiding	 neuronal	 and	 glial	 migration,	 axon	 elongation	 and	 synaptogenesis	 [27]	 [52].	 More	
importantly,	the	role	of	the	EC	signalling	system	in	neurodevelopment	and	maturation	continues	after	
birth	 [24]	 [37],	 as	 prolonged	 exposure	 to	 the	 psychoactive	 cannabinoid	 of	 marijuana,	 D-9-
tetrahydrocannabinol	(D9-THC)	during	adolescence	causes	plastic	changes	in	the	hippocampus	[48].	
Given	the	role	of	the	EC	signalling	system	in	pain	modulation	and	neurodevelopment,	we	sought	to	
investigate	the	role	of	the	EC	system	on	postnatal	maturation	of	pain	processing.	
Here	we	report	significant	age-dependent	plasticity	within	the	supraspinal	EC	system	that	alters	DH	
nociception.	This	paper	maps	these	changes	for	the	first	time	in	both	rodent	and	human	brain	at	a	
molecular	 and	 functional	 level.	 These	 data	 have	 profound	 implications	 for	 our	 understanding	 of	
supraspinal	control	of	spinal	nociception	and	the	treatment	of	pain	in	early	life.	
Materials	and	methods:	
Animals	
Postnatal	day	(P)	3,	14	and	40	Sprague	Dawley	rats	were	purchased	from	Charles	River,	UK.	These	ages	
were	chosen	for	our	study	as	it	spans	across	early	to	late	postnatal	maturation	of	the	rat,	and	pain	
behaviours	reach	maturity	around	P40.	Pups	were	housed	with	their	dams	in	individually	ventilated	
cages	 in	 an	 in-house	 animal	 facility.	 Free	 access	 to	 food	 and	water	 was	 available	 throughout.	 All	
experiments	were	performed	in	P10,	P21	and	P40	rats	during	the	animals’	light	cycle.	Experimental	
procedures	were	 carried	 out	 under	 the	Home	Office	 License	40/3647	 and	 in	 accordance	with	 the	
Animals	(Scientific	Procedures)	Act	1986	and	IASP	guidelines.	Whilst	we	acknowledge	that	this	term	is	
controversial	and	that	rats	at	this	age/weight	are	not	fully	adult,	they	display	many	of	the	behavioural,	
physiological	and	anatomical	responses	seen	in	adults	and	are	routinely	used	as	adults	in	the	entire	
pain	literature.	
Surgery	
PAG	and	RVM	microinjection	animals	were	anaesthetised	with	isoflurane	(Baxter;	Newbury,	Berkshire,	
UK)	and	mounted	on	a	stereotaxic	frame	(Kopf	Instruments,	Tujunga,	CA,	USA).	The	skull	was	exposed	
and	bregma	was	located.	Stereotaxic	coordinates	for	the	ventral	PAG	(vPAG)	and	RVM	were	calculated	
(PAG:	both	P40	and	P21:	left-right	[L-R]	0.5	mm;	anterior-posterior	[A-P]	-7.8	mm;	dorsal-ventral	[D-
V]	-6.0	mm;	P10:	L-R	0.5	mm;	A-P	-7.8	mm;	DV	−4.5	mm;L-R	0.5;	A-P	-7.8mm;	D-V	-4.5mm:	RVM:	P40:	
L-R	0mm,	D-V	-10mm;	A-P	-9.7mm;	P21:	L-R	0mm;	D-V	-10mm;	A-P	-9.2mm;	P10:	L-R	0mm,	D-V	-8mm,	
A-P	-8.7mm)	and	a	26-gauge	2.5-μL	syringe	(Hamilton,	Reno,	NV,	USA)	was	inserted	through	a	drilled	
hole	in	the	skull.	Drugs	were	injected	over	a	5-minute	period,	after	which	the	syringe	was	removed	
and	the	wound	was	closed.	Total	volume	of	drug	administered	into	the	PAG	was	1	μL	and	0.5	μL	to	
the	 RVM	 at	 P21	 and	 P40	 with	 0.5μL	 (PAG)	 and	 0.25μL	 (RVM)	 being	 administered	 to	 P10	 rats	 in	
accordance	with	previously	published	studies	[30;	39];	only	one	drug	was	administered	per	animal.	
Total	brain	volume	is	the	same	between	P21	and	P40	(see	[29])	and	therefore	the	same	volume	for	
injections	were	used.	
Electromyographic	(EMG)	recordings	
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Anaesthesia	(isoflurane)	in	P21	and	P40	rats	was	maintained	with	a	surgically	implanted	endotracheal	
cannula,	whereas	in	P10	rats	it	was	maintained	with	a	fitted	nose	cone.	Isoflurane	concentration	was	
kept	 at	 1.3%	 to	maintain	 light	 anaesthesia,	 as	previously	described	 [29;	 39].	 The	 fur	overlying	 the	
biceps	 femoris	 muscle	 was	 trimmed	 and	 a	 bipolar	 concentric	 needle	 EMG	 recording	 electrode	
(comprising	a	modified	27-gauge	hypodermic	needle;	Ainsworth,	Coventry,	UK)	inserted	into	the	belly	
of	 the	muscle.	 The	EMG	electrode	was	 connected	 to	a	NeuroLog	head-stage	 (NL100AK;	Digitimer,	
Welwyn	Garden	City,	UK),	signals	amplified	×2000	(NL104A),	band-pass	filtered	between	10	and	1000	
Hz	(NL125)	before	being	sampled	at	2	kHz	using	LabChart	software	via	a	PowerLab	data	acquisition	
unit	(AD	Instruments	Ltd.,	Oxford,	UK).	In	these	experiments,	spinal	reflex	excitability	was	determined	
by	the	EMG	activity	of	flexor	hind	limb	muscle	evoked	by	mechanical	stimulation	of	the	plantar	hind	
paw	using	von	Frey	hairs	(vFh).		
Responses	to	2	sub-threshold	vFh	(T-1,	T-2),	and	the	threshold	hair	(T)	and	a	supra-threshold	hair	(T+1)	
were	recorded	and	the	same	4	hairs	used	in	all	subsequent	stimulation	conditions	for	data	analysis.	
Thresholds	were	determined	as	the	vFh	that	produced	an	EMG	response	more	than	10%	greater	than	
the	resting	EMG	activity.	Each	hair	was	then	applied	3	times,	and	the	mean	reading	for	each	of	the	3	
presentations	 recorded.	 Different	 hairs	 were	 used	 in	 each	 age	 group	 as	 mechanical	 withdrawal	
thresholds	 increase	 with	 age.	 A	 stimulus-response	 curve	 of	 EMG	 magnitude	 versus	 mechanical	
stimulus	intensity	was	plotted	and	the	area	under	the	curve	was	calculated	to	provide	an	integrated	
measure	of	spinal	reflex	excitability.	Specific	hairs	used	in	each	age	were	(P10:	15g,	26g,	60g,	100g;	
P21:	26g,	60g,	100g,	180g;	P40:	60g,	100g,	180g,	300g).	
Immunohistochemistry	
P10,	P21	and	adult	rats	were	overdosed	with	intra-peritoneal	(i.p.)	injection	of	sodium	pentobarbital	
(P21	 and	 adults,	 2mL;	 P10,	 1mL).	 Animals	 were	 then	 transcardially	 perfused	 with	 4%	
paraformaldehyde	and	brains	quickly	dissected.	The	PAG	and	the	RVM	were	sectioned		(40μm)	on	a	
freezing	microtome	(Leica,	SM2010R).	
Tissue	was	blocked	with	3%	serum	with	0.3%	triton	X100	(Sigma	Aldrich)	for	1	hour	before	incubation	
with	primary	 antibody.	 The	primary	 antibodies	used	were	 goat	 anti-CB1	 (Frontier	 Institute,	 Japan,	
1:200	[31]).	This	antibody	has	been	validated	previously	in	rat	tissueSections	were	incubated	with	this	
antibody	overnight	at	room	temperature.	Following	incubation	with	the	primary	antibody,	sections	
were	incubated	with	Alexa-Fluor	(Invitrogen,	UK)	conjugated	secondary	antibodies	(1:500)	for	2	hours	
at	room	temperature.		
Immunofluorescent	 sections	were	observed	with	 a	 Leica	 IRE2	 fluorescence	microscope	 fitted	with	
Hammamatsu	OrcaER	monochrome	camera	and	captured	using	Volocity	6.1	software	(Perkin	Elmer,	
UK).	Same	exposure	time	of	image	acquisition	was	used	for	each	sections	staining	for	the	different	
antibodies	from	the	different	animals	to	ensure	consistent	brightness	in	images.	Image	J	1.29	(NIH)	
was	 used	 to	 adjust	 brightness	 and	 contrast	 of	 the	 images	 post-acquisition.	 Systematic	 random	
sampling	and	unbiased	stereological	methods	were	used	for	quantification	semi-quantitative	analysis	
as	adopted	from	previously	published	studies	[42;	44].		
TaqMan	real-time	polymerase	chain	reaction	(RT-PCR)	
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Human	brain	tissue	was	obtained	from	the	Nottingham	BioBank.		Ethical	approval	for	this	study	was	
sought	and	granted	(Study	ACP0000100)	and	studies	conducted	in	Human	Tissue	Act	(2004)	registered	
laboratories.	 	 Tissue	was	 selected	 to	 come	 from	 cases	 aged	 25-29	weeks	 gestation,	 38-39	weeks	
gestation	and	older	than	2	years.		Cause	of	death	was	provided	and	included	transcervical	ascending	
infection/	 foetal	 inflammatory	 syndrome,	 uteroplacental	 perfusion	 deficiency	 (UPPD)	 (1	 with	
concomitant	Streptococcus	B	infection),	osteoskeletal	dysplasia,	multiple	congenital	malformations,	
placental	villous	dysmaturity	or	no	significant	abnormality.	Tissue	was	provided	as	paraffin	embedded	
blocks	including	the	midbrain,	pons	and	medulla.		RT-PCR	was	conducted	on	10μm	sections	from	each	
block	following	the	same	procedure	as	described	below.	Primers	and	probes	for	the	human	sequences	
were	designed	in	an	analogous	manner	to	that	stated	below.	
P10,	P21	and	P40	rats	were	overdosed	with	intra-peritoneal	(i.p.)	injection	of	sodium	pentobarbital	
(P21	and	P40s,	2mL;	P10,	1mL).	Their	brains	were	quickly	dissected	out	on	ice.	Tissue	from	the	PAG	
and	RVM	were	isolated.	Samples	were	flash	frozen	in	liquid	nitrogen	and	stored	at	-80ºC.	
TaqMan	quantitative	RT-PCR	was	performed	using	 the	StepOnePlus	 real-time	PCR	system	(Applied	
Biosystems,	 Forster	 City,	 CA,	 USA).	 Primers	 and	 probes	 for	 glyceraldehyde	 3-phosphate	
dehydrogenase	(GAPDH;	National	Center	for	Biotechnology	 Information	[NCBI]	reference	sequence	
NM_017008.3),	 CB1	 receptor	 (NM_012874.4),	 CB2	 receptor	 (NC_005104.4),	 GPR55	 receptor	
(XM_006245494.1),	NAPE-PLD	(NM_199381.1)	and	DAGLα	(NM_006133.2)	were	designed	on	Primer	
Express	3	(Applied	Biosystems).	Each	sample	was	run	in	triplicates.	Expression	of	target	genes	were	
normalised	 to	GAPDH,	and	expression	of	 target	genes	was	determined	using	 the	 relative	 standard	
curve	method.	All	sequences	for	primers	were	validated	with	a	BLAST	search.	
LC-MS/MS	Analysis	of	Endocannabinoids		
P10,	21	and	40	rats	were	killed	by	overdose	of	i.p.	sodium	pentobarbital,	PAG	and,	RVM	tissue	were	
dissected	and	frozen	in	liquid	nitrogen.	
An	LC-MS/MS	method	was	used	for	analysis	of	ECs	based	on	a	previously	published	method	[69].	
Internal	standards	of	100 μL	of	2-AG-d8	(10 μM)	and	15 μL	of	AEA-d8	(28 μM)	were	added	to	each	
tissue	sample	or	EC	standards	and	vortexed	briefly.	Ethyl	acetate : hexane	(9 : 1	v/v)	was	added	to	
each	sample,	vortex-mixed	(10 min),	and	centrifuged	(13000 rpm,	10 min,	4°C).	The	procedure	was	
repeated	and	the	supernatants	pooled	and	evaporated	using	a	vacuum	centrifugal	evaporator.	Prior	
to	analysis,	each	sample	extract	was	reconstituted	in	100 μL	of	acetonitrile.	The	injection	volume	
was	10 μL.	EC	standards	(AEA,	2-AG,	OEA,	PEA,	and	internal	standards	2-AG-d8,	AEA-d8)	were	
purchased	from	Axxora	Laboratory	services,	Bingham,	Nottingham,	UK.	The	HPLC	system	used	was	a	
Shimadzu	SCL	10Avp	(Shimadzu,	Columbia,	MD,	USA)	coupled	to	a	triple	quadrupole	ion-trap	4000	
QTRAP	mass-spectrometer	(AB	SCIEX,	UK)	equipped	with	Turbo	Spray	ionisation	interface.	Analytes	
were	separated	chromatographically	on	a	Waters	Symmetry	C18	column	(internal	diameter	100	×	
2.1 mm,	particle	size	3.5 μm)	with	a	mobile	phase	flow	rate	of	0.3 mL/minute.	Multiple-reaction	
monitoring	of	individual	compounds	using	specific	precursor	and	product	mass-to-charge	(m/z)	
ratios	allowed	simultaneous	measurement	of	AEA,	2-AG,	OEA,	and	PEA.	Quantification	was	by	the	
internal	standard	method	with	extracted	calibration	standards	and	data	analysis	was	done	using	
Analyst	v	1.4.2	(AB	SCIEX,	UK).	
Statistics	
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All	 individual	data	points	were	 represented	as	mean	±	 SEM.	EMG	data	were	normally	distributed.	
Statistical	comparisons	between	the	age	groups	and	drugs	were	made	using	two-way	ANOVA	or	one-
way	ANOVA	with	Bonferroni	multiple	comparisons.	Statistical	comparison	between	the	age	groups	for	
the	 expression	 of	 various	 endocannabinoid	 targets	 in	 mass	 spectrometry,	 TaqMan	 and	 RT-PCR	
experiments	were	made	by	one-way	ANOVA	with	Bonferroni	multiple	comparisons.	
Results:	
The	expression	of	ECs	are	developmentally	regulated	in	the	PAG	and	RVM	
We	firstly	measured	the	concentrations	of	endogenous	CB1	receptor	ligands	anandamide	(AEA)	and	
2-arachidonoylglycerol	(2-AG),	in	the	PAG	and	RVM	of	postnatal	day	(P)10,	P21	and	P40	rats	by	tandem	
liquid	 chromatography-mass	 spectrometry	 (LC-MS/MS).	 In	 the	 PAG	 (Fig	 1A)	 and	 RVM	 (Fig	 1B)	 the	
levels	of	AEA	significantly	increased	during	the	early	postnatal	period,	and	reached	mature	levels	by	
P21.	Similarly	2-AG	levels	in	the	PAG	(Fig	1C)	and	RVM	(Fig	1D)	also	increased	and	reached	mature	
levels	 by	 P21.	 Consistent	 with	 previous	 reports,	 the	 measured	 concentration	 of	 2-AG	 is	 higher	
compared	to	anandamide	in	the	brain	regions	tested,	as	AEA	is	measured	in	pmol/g	range	whereas	2-
AG	 in	 nmol/g	 range	 [8].	 Collectively	 these	 data	 indicate	 that	 the	 expression	of	 ECs	 increases	with	
postnatal	age	of	the	rat.		
Oleoylethanolamine	 (OEA)	 and	 palmitoylethanolamine	 (PEA)	 were	 also	 measured	 (Supp.	 Fig.	 1).	
Although	OEA	and	PEA	lack	affinity	at	CB1	and	CB2	receptors	[10],	they	exert	similar	effects	as	other	
synthetic	 cannabinoids,	 via	 the	 peroxisome	 proliferator-activated	 receptor-alpha	 (PPAR-α),	 GPR55	
and	GPR119	receptors	[13;	57].	There	were	no	changes	in	PEA	levels	in	the	PAG	(Supp.	Fig.	1A),	but	
PEA	 levels	 in	 the	 RVM	 increased	with	 postnatal	 age	 and	was	 highest	 in	 P40s	 (Supp.	 Fig.	 1B).	 The	
concentration	of	OEA	in	the	PAG	and	RVM	also	increased	with	postnatal	age	and	similarly,	expression	
was	highest	in	P40s	(Supp.	Fig.	1C,	D).		
We	 next	 assessed	 whether	 the	 expression	 of	 endocannabinoid	 synthesising	 enzymes	 N-acyl	
phosphatidylethanolamine-specific	 phospholipase	 D	 (NAPE-PLD;	 synthesising	 anandamide)	 and	
diacylglycerol	 lipase	alpha	(DAGLα;	synthesising	2-AG)	also	 increase	with	postnatal	age.	 In	the	PAG	
and	RVM	we	undertook	PCR	investigations.	We	isolated	mRNA	from	the	ventrolateral	PAG	(vPAG)	(Fig.	
1E)	and	the	RVM	(Fig.	1F)	of	P10,	21	and	P40	rats.	We	focused	on	the	vPAG	as	neurons	from	this	region	
indirectly	project	to	the	DH	via	the	RVM	[3;	61].	The	transcript	levels	of	target	genes	were	normalised	
to	the	expression	of	GAPDH	in	the	same	tissue	and	quantification	was	performed	using	the	relative	
standard	curve	method	[39].		
In	 the	 vPAG,	 NAPE-PLD	mRNA	 transcript	 levels	 increased	 as	 the	 rats	 aged,	 and	 NAPE-PLD	mRNA	
transcript	 levels	 were	 higher	 in	 P40s	 compared	 to	 P10	 (Fig.	 1E).	 No	 differences	 in	 DAGLα	mRNA	
transcript	levels	(Fig.	1E)	were	observed	in	the	vPAG	between	the	ages.	In	the	RVM,	no	differences	in	
DAGLα	and	NAPE-PLD	mRNA	transcript	levels	were	observed	between	the	ages	(Fig.	1F).	
To	 investigate	whether	our	 results	 are	 translational	 in	humans,	we	also	measured	mRNA	 levels	of	
NAPE-PLD	 in	 the	midbrain	of	post-mortem	human	 tissue	deposited	 in	 the	Nottingham	BioBank	by	
TaqMan	qRT-PCR.	Tissues	were	selected	to	span	a	range	of	ages	from	subjects	that	were	born	pre-
term	 (24-26	 weeks	 post-conceptional	 age,	 n=8),	 full-term	 (39-40	 weeks	 post-conceptional,	 n=8),	
infants	 (3-8	 months,	 n=8)	 and	 adults	 (14-60	 years,	 n=4).	 mRNA	 levels	 were	 measured	 using	 a	
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geometric	mean	 of	 reference	 genes	 (cyclophilin	 A	 and	 hydroxymethylbilane	 synthase).	We	 found	
NAPE-PLD	mRNA	transcript	level	was	higher	in	infants	compared	to	both	pre-term	and	full-term	(Fig.	
1G),	 which	 suggests	 that	 like	 the	 rat,	 expression	 of	 EC-synthesising	 enzymes	 undergo	 significant	
postnatal	modulation	during	development	in	humans.	
The	expression	of	cannabinoid	receptors	also	undergo	significant	postnatal	refinement	
Results	from	our	previous	experiments	implied	that	the	expression	of	ECs	within	brainstem	nuclei	is	
upregulated	 as	 rats	mature.	 Therefore,	 we	 sought	 to	 understand	whether	 there	 is	 also	 postnatal	
modification	of	EC	receptors	within	these	brainstem	nuclei.	Expression	of	the	CB1,	CB2	and	GPR55	
receptors	in	the	rat	were	examined	using	TaqMan	RT-PCR.	The	expression	of	CB1	and	CB2	receptors	
in	human	midbrain	were	studied	using	TaqMan	RT-PCR	and	in	situ	hybridisation	techniques.		
In	the	rat	PAG,	CB1	mRNA	transcript	levels	decreased	with	age	but	this	trend	did	not	reach	statistical	
significance	 (Fig.	 2A).	 Immunohistochemistry	 demonstrated	 CB1	 staining	was	mostly	 diffuse	 fibres	
(Fig.	 2B),	 found	 at	 the	 axonal	 terminals,	 consistent	 with	 previously	 published	 findings	 [62].	 CB1	
immunoreactivity	was	particularly	dense	in	the	region	immediately	adjacent	to	the	cerebral	aqueduct.	
Staining	intensity	analysis	showed	that	CB1	receptor	immunoreactivity	decreased	as	the	rats,	and	was	
highest	at	P10	(Fig.	2C).	In	the	rat	RVM,	no	age-related	differences	in	CB1	mRNA	transcript	levels	were	
observed	 (Fig.	 2D).	 However	 using	 immunohistochemistry	 we	 found	 significant	 differences	 in	 the	
expression	 pattern	 of	 CB1	 within	 the	 NRM	 specifically	 during	 postnatal	 development.	
Immunoreactivity	for	CB1	receptors	increased	during	postnatal	development,	and	reached	adult	levels	
by	P21	(Fig.	2E&F).	No	differences	in	CB2	receptor	mRNA	transcript	levels	were	observed	in	the	vPAG	
between	the	ages	(Fig.	3A).	Similarly	we	found	no	changes	in	CB2	transcript	levels	in	the	RVM	(Fig	3B).		
No	changes	in	GPR55	mRNA	expression	were	observed	in	the	PAG	(Fig.	3C)	but	significant	postnatal	
refinement	to	the	expression	of	GPR55	mRNA	was	detected	in	the	RVM	with	levels	transiently	and	
significantly	upregulated	at	P21	(Fig.	3D).	
In	 the	 human	midbrain,	 no	 changes	 in	 the	 expression	 of	 either	 CB1	 or	 CB2	 receptor	mRNA	were	
observed	 (Fig.	 4A,	 B).	 To	 examine	 the	 pattern	 of	 mRNA	 expression	 in	 human	 tissue,	 in	 situ	
hybridisation	 techniques	were	used	 to	 investigate	 the	expression	of	CB1	and	CB2	 receptors	 in	 the	
midbrain	of	human	pre-term,	 full-term,	 infants	and	P40s	 (Fig.	4C-F).	Counting	of	CB1	positive	cells	
revealed	that	the	expression	of	CB1	receptors	is	lowest	in	P40s	compared	to	earlier	ages	(Fig.	4C&D).	
There	were	no	differences	in	CB1	receptor	mRNA	expression	between	pre-term,	full-term	and	infants.	
There	were	also	no	changes	in	the	expression	of	CB2	receptor	protein	between	the	age	groups	tested	
(Fig.	4E&F).		
These	findings	suggest	that	unlike	the	ECs	and	EC-synthesising	enzymes,	the	expression	of	CB1,	CB2	
and	GPR55	receptors	within	the	PAG	are	not	developmentally	 regulated,	however	within	the	RVM	
GPR55	mRNA	transcription	is	increased	for	a	short	period	around	P21.	Our	results	also	show	that	in	
the	human	mid-brain,	the	expression	of	CB1	receptors	undergo	significant	postnatal	refinement	and	
are	highest	during	early	infancy	and	childhood.		
CB1/CB2	receptors	in	brainstem	nuclei	inhibit	nociceptive	reflex	in	both	P21	and	P40	rodents			
The	 functional	 significance	 of	 the	 developing	 EC	 signalling	 system	 on	 nociceptive	 reflexes	 were	
investigated	by	pharmacologically	activating	cannabinoid	receptors	within	brainstem	nuclei	in	lightly-
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anaesthetised	 rats	 at	 different	 developmental	 timepoints.	 Various	 synthetic	 cannabinoids	 were	
microinjected	into	either	the	vPAG	or	the	RVM	of	each	rat,	and	electromyographic	(EMG)	recordings	
were	 performed	 before	 and	 after	 drug	 administration	 in	 the	 bicep	 femoris	 muscle	 to	 assess	
withdrawal	reflexes	to	mechanical	stimulation	of	the	hindpaw	using	callibrated	von	Frey	hairs	(vFh).	
In	our	first	experiment,	WIN55212	(4μg,	CB1	and	CB2	receptor	agonist)	was	microinjected	into	the	
PAG	of	postnatal	day	 (P)21	and	P40	 rats,	as	previously	experiments	 showed	a	 functional	 switch	 in	
descending	pain	modulation	between	these	ages	(Supp.	Fig.	2)	[29;	30;	39;	55].	Intra-PAG	WIN55212	
significantly	 reduced	 spinal	 reflex	 excitability	 (Supp.	 Fig.	 2C)	 and	 increased	mechanical	withdrawal	
thresholds	 (Supp.	 Fig.	 2D)	 in	both	P21	and	P40	 rats	 compared	 to	 vehicle	 controls.	 The	 increase	 in	
mechanical	withdrawal	threshold	was	significantly	greater	in	P40	rats	compared	to	P21.		
To	further	investigate	the	consequences	of	activating	cannabinoid	receptors	on	nociceptive	reflexes,	
HU210	(4µg,	CB1	and	CB2	receptor	agonist)	was	microinjected	injected	into	the	vPAG	or	the	RVM	of	
P10,	P21	and	P40	rats	(Fig.	5).	PAG	microinjection	of	HU210	potently	reduced	spinal	reflex	excitability	
compared	to	vehicle	controls	in	all	age	groups	tested	(Fig.	5A).	A	reduction	in	spinal	reflex	excitability	
was	accompanied	by	an	increase	in	mechanical	withdrawal	threshold	(Fig.	5B).	The	same	pattern	was	
seen	 when	 HU210	 was	 microinjected	 in	 the	 RVM	 (Fig.	 5	 C&D).	 Intra-PAG	 HU210	 induced	 anti-
nociceptive	 effects	 were	 stronger	 in	 P21	 and	 P40	 animals	 compared	 to	 P10	 (Fig.	 5A,	 B)	 with	 the	
greatest	effect	of	HU210	being	observed	at	P21	(Fig.	5C,	D).		
	
Collectively	 these	 data	 showed	 that	 functional	 activation	 of	 CB1	 and	 CB2	 receptors	 within	 the	
descending	pain	pathway	 is	anti-nociceptive	 throughout	postnatal	development.	 In	addition,	 some	
age-related	differences	were	observed	(increased	efficacy	of	HU210	at	P21),	which	suggest	that	EC	
signalling	 via	 the	 CB1	 and	 CB2	 receptors	 undergo	 significant	 refinement	 over	 the	 early	 postnatal	
period.	
Supraspinal	GPR55	receptor	mediated	analgesia	in	early	life	
We	 next	 tested	 the	 effects	 of	 decreasing	 cannabinoid	 receptor	 activity	 on	 nociceptive	 processing	
during	 postnatal	 maturation.	 Intra-PAG	 microinjection	 of	 AM251	 (2.77	 and	 1.35µg,	 CB1	 receptor	
inverse	agonist)	had	no	effect	on	spinal	reflex	excitability	in	P40	rats	compared	to	vehicle	controls	(Fig.	
6A)	and	had	no	effect	upon	mechanical	withdrawal	threshold.	However,	intra-PAG	AM251	(2.77µg)	
significantly	inhibited	spinal	reflex	excitability	in	P10	and	P21	rats.	Mechanical	withdrawal	thresholds	
were	increased	after	intra-PAG	AM251	in	P21	rats	only	(Fig.	6B).	Similarly,	intra-RVM	AM251	(2.77µg)	
significantly	reduced	spinal	reflex	excitability	and	increased	mechanical	withdrawal	thresholds	in	P10	
and	P21	rats	compared	to	vehicle	control	(Fig.	6C,	D).	This	result	is	surprising	as	both	agonist	(HU210)	
and	inverse-agonist	(AM251)	mediate	the	same,	effect	upon	spinal	nociception	in	younger	animals.		
In	 addition	 to	 a	 role	 as	 a	 CB1	 receptor	 inverse	 agonist,	 AM251	 is	 also	 known	 to	 activate	 GPR55	
receptors	[33].	Lysophophotidylinositol	(LPI)	is	known	to	be	an	endogenous	agonist	of	this	receptor	
[45].	Similar	to	the	effect	of	AM251,	intra-PAG	microinjection	of	LPI	(12μg)	significantly	reduced	spinal	
reflex	excitability	in	P10	and	P21	rats	compared	to	vehicle	controls	(Fig.	6A)	and	significantly	increased	
mechanical	 withdrawal	 threshold	 in	 P21	 rats	 (Fig.	 6B).	 Intra-RVM	 LPI	 significantly	 reduced	 reflex	
excitability	in	P10	and	P21	rats	compared	to	controls	(Fig	6C)	and	increased	mechanical	withdrawal	
thresholds	 in	 both	 P10	 and	 P21	 rats	 (Fig.	 6D).	 In	 P40	 rats,	 neither	 intra-PAG	 nor	 intra-RVM	
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microinjection	 of	 LPI	 had	 an	 effect	 on	 mechanical	 withdrawal	 thresholds,	 but	 intra-RVM	 LPI	
significantly	increased	spinal	reflex	excitability	when	compared	to	vehicle	controls.	
To	fully	elucidate	whether	AM251	was	acting	via	the	GPR55	receptors,	and	address	the	concern	of	
using	 a	 higher	 dose	 (2.77µg),	 we	 assessed	 the	 effects	 of	 low	 dose	 (1.35µg)	 AM251,	 on	 spinal	
excitability	in	P21	and	P40	rats	when	administered	to	the	vlPAG.	Similar	to	our	previous	observations,	
low	dose	AM251	(1.35	µg)	had	no	effect	in	the	P40	but	reduced	spinal	reflex	excitability	in	P21	rats	
(Fig	6E).	 	Next,	we	tested	the	effect	of	blocking	GPR55	receptors	 in	the	vlPAG	of	P21	rats	with	the	
GPR55	 antagonist,	ML	 193	 (1µg).	 	 Co-administration	 of	ML193	with	AM251	 (1.35µg)	 reversed	 the	
ability	of	AM251	to	decrease	spinal	excitability	in	P21	rats	(Fig	6E).	Moreover,	a	significant	decrease	
in	spinal	reflex	excitability	was	observed	with	both	the	lower	dose	(1.35µg)	and	higher	dose	(2.77	µg)	
compared	 to	P21	animals	 receiving	 co-administration	AM251	and	ML193.	 These	 findings	provided	
further	support	in	the	role	of	GPR55	on	antinociception	via	descending	control	systems	early	in	life.		
Discussion:	
Previous	research	has	identified	several	postnatal	modifications	within	the	pain	pathway	that	impact	
upon	the	development	of	functional	nociception.		These	include:	alterations	in	terminations	of	primary	
afferent	 sensory	 neurones	 within	 the	 DH	 [6];	 immature	 neuro-immune	 interactions[5];	 and	 a	
fundamental	shift	in	supraspinal	control	over	DH	excitability,	from	predominantly	excitatory	in	early	
life	to	inhibition	after	the	third	postnatal	week	[29;	54].		
As	described	elsewhere,	the	EC	signalling	system	is	essential	 for	normal	brain	maturation	and	pain	
processing	[36].		In	our	studies	we	report	postnatal	alternations	in	the	expression	of	EC-related	targets	
in	 the	 midbrain	 of	 humans	 and	 brainstem	 nuclei	 of	 the	 rat,	 and	 these	 changes	 have	 significant	
functional	 consequences	 on	 pain	 modulation.	 Interestingly,	 our	 data	 also	 reveal	 a	 novel	 role	 for	
GPR555	receptors	in	pain	modulation	during	the	early	postnatal	period,	as	the	expression	of	GPR55	
receptor	mRNA	was	highest	 in	the	early	adolescent	period	of	the	rat,	and	supraspinal	activation	of	
GPR55	receptors	strongly	inhibited	nociceptive	reflexes	in	early	infancy	and	adolescence	of	the	rat.		
Altogether	 our	 research	 provides	 further	 insights	 to	 our	 understanding	 in	 the	maturation	 of	 pain	
signalling	systems	during	postnatal	development.	
The	expression	of	endocannabinoids	within	the	brainstem	nuclei	during	postnatal	development	
This	is	the	first	study	of	its	kind	to	measure	both	expression	of	EC	and	EC-targets	within	the	brainstem	
nuclei	in	both	rat	and	human	brains.	Our	major	finding	is	that	ECs	in	the	rat	PAG	and	RVM	increases	
with	postnatal	age.	LC-MS/MS	analysis	showed	significant	increases	in	the	levels	of	AEA	in	both	the	
PAG	and	the	RVM,	in	parallel	with	this	the	expression	of	NAPE-PLD	mRNA	in	the	PAG	increased	as	the	
animals	aged,	and	reached	maturity	by	the	third	postnatal	week	in	the	rat.	In	humans,	expression	of	
NAPE-PLD	mRNA	 in	 the	midbrain	was	highest	 in	 infants	 compared	 to	both	pre-term	and	 full-term	
neonates.	Altogether,	these	findings	suggest	that	expression	of	AEA	increases	within	brainstem	nuclei	
of	 mammals	 during	 postnatal	 development.	 Importantly,	 due	 to	 the	 nature	 of	 human	 tissue	 we	
obtained	 for	 this	 study,	early	 life	 inflammation	 could	also	 contribute	 to	 changes	 in	 the	expression	
NAPE-PLD	 mRNA	 transcript	 levels	 during	 infancy.	 Therefore,	 future	 experiments	 with	 a	 different	
cohort	of	human	tissue	would	provide	further	insight.		
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The	levels	of	other	ECs,	such	as	2-AG,	also	increase	with	postnatal	age	in	the	RVM	of	the	rat.	In	our	
study	only	subtle	changes	were	detected	in	the	expression	of	the	2-AG	synthesising	enzyme,	DAGLα.	
No	 changes	 were	 detected	 in	 the	 expression	 of	 DAGLα	 mRNA	 within	 the	 brainstem	 nuclei.	 The	
disparity	 between	DAGLα	 expression	 pattern	 and	 levels	 of	 2-AG	may	 be	 explained	 by	 the	 greater	
availability	 of	 the	 substrate	 for	 the	 production	 of	 2-AG	 or	 to	 age-related	 post-translational	
modifications,	it	has	been	shown	that	2-AG	can	be	synthesised	independently	of	DAGLα	activity:	PIP2	
can	 be	 catalysed	 into	 2-arachidonoya-lysophospholipid	 by	 phospholipase	 A1,	 which	 is	 in	 turn	
hydrolysed	by	lyso-PLC	to	become	2-AG	[47].		
The	expression	of	cannabinoid	receptors	within	the	brainstem	nuclei	during	postnatal	development	
We	 did	 not	 find	 significant	 changes	 in	 the	 expression	 of	 either	 CB1	 or	 CB2	 receptor	 mRNA	 with	
postnatal	age,	in	both	rats	and	humans.	However,	in	situ	hybridisation	experiments	showed	that	the	
number	 CB1	 receptor	 positive	 cells	 in	 human	 midbrain	 were	 highest	 during	 infancy	 and	
immunohistochemical	 expression	 of	 CB1	 receptor	 underwent	 postnatal	 modification	 within	 the	
brainstem	nuclei	of	the	rat.	In	line	with	previous	published	findings	[7;	18],	within	the	rat	PAG,	CB1	
receptor	 expression	 were	 found	 closely	 along	 the	 lining	 of	 the	 aqueduct,	 and	 staining	 intensity	
decreased	as	 the	animals	agedWe	also	 found	an	 increase	 in	CB1	receptor	 immunoreactivity	 in	 the	
RVM,	The	disparity	between	mRNA	and	immunohistochemical	data	implies	that	changes	in	expression	
and	function	of	the	receptor	may	reflect	differences	in	the	translation	of	mRNA	rather	than	changes	
in	 gene	 transcription.	 Additionally	 it	 should	 be	 recognised	 that	 immunohistochemically	 verified	
visualisation	of	receptor	may,	in	cases	of	fibre	staining,	reflect	alterations	in	expression	within	cells	in	
other	CNS	centres	that	innervate	the	PAG	or	RVM.		Nonetheless,	expression	of	CB1	receptors,	at	the	
protein	level	decreased	in	human	midbrain	and	rat	PAG	with	postnatal	age.	
GPR55	mRNA	was	detected	in	all	the	regions	tested	(Figure	6.13).	The	overall	expression	was	lower	
compared	to	other	endocannabinoid	related	targets.	Within	the	RVM,	GPR55	mRNA	peaked	at	P21,	
which	 again	 echoes	 the	 theme	 that	 P21	 is	 a	 critical	 timepoint	 when	 developmentally	 regulated	
changes	occur.	In	this	study	immunohistochemical	localisation	of	GPR55	receptors	was	attempted	but	
due	to	technical	reasons	was	unsuccessful.	Validation	of	the	quantification	of	the	mRNA	levels	of	CB2	
and	GPR55	receptors	was	attempted	with	immunohistochemistry	as	part	of	this	wide	ranging	study.		
However	it	was	impossible	for	us	to	validate	the	specificity	of	the	antibodies	against	their	respective	
targets	and	therefore	these	data	are	not	presented	in	this	paper.	
The	functional	role	of	cannabinoid	receptors	in	nociception	during	postnatal	development	
In	 this	 study,	 we	 examined	 the	 role	 of	 cannabinoid	 receptors	 in	 the	 brainstem	 on	 nociceptive	
processing	 during	 postnatal	maturation.	We	 pharmacologically	manipulated	 cannabinoid	 receptor	
activity	by	in	vivo	intra-cerebral	microinjections.	Whilst	we	specifically	targeted	the	vlPAG	and	RVM,	
there	is	a	slight	possibility	that	the	drugs	we	administered	could	potentially	diffuse	into	neighbouring	
regions	 within	 the	 brainstem.	 Nonetheless,	 we	 showed	 that	 activation	 of	 CB1/2	 receptors	 in	 the	
brainstem	regions	at	any	of	the	ages	tested	was	always	inhibitory.	Initially	WIN55212	was	injected	into	
the	PAG	of	P21	and	P40	rats,	which	was	antinociceptive	in	both	ages.	HU210	was	used	in	subsequent	
experiment	as	a	CB1/CB2	agonist	because	HU210	 is	about	a	hundred	 fold	more	potent	at	 the	CB1	
receptors	than	WIN55212	(Ki	for	CB1	receptors,	HU210	=	0.061nM,	WIN55212	=	62.3nM).	Application	
of	HU210	 in	 the	PAG	and	 the	RVM	also	 reduced	nociceptive	behaviours	 in	all	 ages	 tested,	 further	
indicating	that	CB1/CB2	agonism	is	analgesic	throughout	postnatal	development.		
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These	findings	imply	that	although	the	expression	of	components	ofthe	ECs,		change	with	postnatal	
age,	EC	dependent	nociceptive	processing	within	the	descending	pathway	via	CB1	and	CB2	receptors	
is	 not	 developmentally	 regulated.	 This	 is	 in	 line	 with	 observations	 from	 previous	 studies,	 where	
systematic	administration	of	CB1/CB2	agonists,	 including	WIN55212,	CP55940	and	HU210	inhibited	
nociceptive	responses	in	young	and	adult	rats	[9;	20;	35;	51].	More	importantly,	it	is	known	that	the	
opioid	and	cannabinoid	signalling	system	work	synergistically	within	pain	modulatory	pathways	[12;	
14;	63].	Given	that	1)	significant	postnatal	refinement	occurs	within	opioid-mediated	pain	modulation	
pathway	[30;	39],	and	2)	ECs	play	a	trophic	role	in	development,	it	 is	 likely	that	the	increase	in	ECs	
contribute	to	maturation	of	opioid	signalling	during	the	postnatal	period	and	this	possibility	warrants	
further	investigation.	
We	 also	 demonstrate	 an	 exciting	 new	 cannabinoid	 target	 for	 the	 treatment	 of	 pain	 in	 early	 life.	
Changes	in	the	physiological	functions	of	EC	signalling	system	were	revealed	when	we	activate	GPR55	
receptors,	by	microinjecting	LPI	into	the	PAG	and	the	RVM.	Notably,	intra-PAG	or	RVM	administration	
of	LPI	reduced	spinal	reflex	excitability	and	increased	mechanical	withdrawal	thresholds	in	P10	and	
P21	rats.	Whereas	in	P40s,	a	mild	increase	in	spinal	reflex	excitability	was	observed	after	intra-RVM	
microinjection	of	LPI.	The	effect	of	LPI	on	P40	spinal	reflex	excitability	reported	in	our	study	is	line	with	
observations	in	other	studies.	We	further	substantiated	the	age-dependent	role	of	GPR55	mediated	
signalling	in	the	PAG	by	blocking	the	ability	of	AM251	to	produce	decreased	spinal	excitability	in	P21	
rats	 with	 the	 specific	 GPR55	 receptor	 antagonist	 ML	 193.	 	 The	 general	 consensus	 is	 that	 GPR55	
receptor-mediated	activity	is	most	likely	to	be	pro-nociceptive	in	mature	animals	[16].	The	receptor	in	
the	mature	CNS	is	coupled	to	the	Gq	proteins,	and	when	activated	causes	an	increase	in	intracellular	
calcium	 levels	 and	 synaptic	 excitability	 [16;	 59],	 whereas	 CB1	 activation	 negatively	 couples	 to	
adenylate	cyclase	activity	via	Gi	proteins..	It	has	also	been	shown	that	intraplantar	injection	of	LPI	(2	
pmol)	leads	to	allodynia	in	P40	mice	[25].		
Nonetheless,	results	from	this	study	indicated	that	LPI	in	P40	RVM	was	pronociceptive	whereas	in	the	
immature	PAG	and	RVM	were	antinociceptive,	which	suggests	a	switch	 in	GPR55	mediated	actions	
throughout	postnatal	development.	Recently	 it	has	been	shown	 that	GPR55	expressed	on	primary	
afferent	nociceptors	is	activated	by	lyso-phosphatidyl-β-D-glucoside,	released	from	spinal	radial	glia	
[27].		This	interaction	was	essential	for	the	maturation	of	spinal	nociceptive	circuits	as	disruption	of	it	
led	 to	mis-allocation	of	nociceptive	axons	 into	proprioceptive	 zones	 in	 the	DH.	 Supraspinal	GPR55	
receptors	may	also	have	a	similar	neurodevelopmental	role,	and	this	warrants	further	investigation.	
The	role	of	the	EC	signalling	system	in	maturation	of	pain	processing	during	the	postnatal	period	
In	summary,	our	data	imply	that	the	EC	signalling	system	is	a	promising	target	for	pain	management	
in	 immature	patients.	 Activation	of	 CB1	 and	CB2	 receptors	 in	 the	brainstem	nuclei	 is	 always	 anti-
nociceptive	regardless	of	postnatal	age.	In	addition,	activation	of	supraspinal	GPR55	receptors	is	only	
anti-nociceptive	in	young	animals,	revealing	fundamental	development	in	the	physiological	functions	
of	the	EC	signalling	system	during	postnatal	development,	and	GPR55	receptors	as	a	novel	target	for	
paediatric	analgesic.		
Concurrent	with	the	postnatal	develoment	of	the	physiological	functions	of	the	EC	signalling	system,	
anatomical	studies	imply	that	the	expression	of	ECs	within	brainstem	nuclei	increases	with	postnatal	
age.	This	anatomical	 refinement	may	be	 important	 for	endogenous	pain	 inhibition	 throughout	 the	
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postnatal	period,	 	and	mediating	the	maturation	of	synaptic	connections	within	 the	pain	signalling	
pathway.		
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Fig.	 1	 Changes	 in	 the	 expression	 of	 endocannabinoids	 (eCBs)	 and	 eCB-synthesising	 enzymes	 in	
brainstem	 nuclei	 of	 the	 rat	 and	 human	 midbrain	 during	 postnatal	 development.	 (A-B)	 Mass	
spectrometry	analysis	of	anandamide	levels	in	periaqueductal	grey	(PAG)	and	rostroventral	medulla	
(RVM).	The	expression	of	anandamide	 increased	during	early	postnatal	development,	and	reached	
maturity	by	postnatal	day	(P)21.	(p<0.05	in	PAG	and	RVM;	one-way	ANOVA).	(C-D)	Mass	spectrometry	
analysis	of	2-AG	levels	in	PAG	and	RVM.	No	changes	in	the	expression	of	2-AG	were	observed	in	the	
PAG	(C).	The	expression	of	2-AG	increased	during	early	postnatal	development,	and	reach	maturity	by	
P21	 in	 the	RVM	(D;	p<0.01;	one-way	ANOVA).	 (E)	Taqman	RT-PCR	analysis	of	 the	eCB-synthesising	
enzymes	NAPE-PLD	and	DAGLα	in	vPAG.	The	expression	of	NAPE-PLD	mRNA	increased	during	early	
postnatal	 development	 and	 reach	maturity	 by	 P21	 (p<0.05;	 one-way	ANOVA).	 (F)	 Taqman	RT-PCR	
analysis	of	NAPE-PLD	and	DAGLα	in	RVM.	No	significant	changes	were	observed.	(G)	The	expression	
of	NAPE-PLD	mRNA	was	highest	in	human	infant	midbrain	compared	to	all	other	age	groups	tested	
(p<0.01;	one-way	ANOVA).	9-11	animals	per	age	group	used	for	mass	spectrometry	experiments.	3-4	
animals	 per	 age	 group	 for	 Taqman	 RT-PCR	 and	 immunohistochemical	 experiments.	 4-8	 human	
midbrain	tissue	per	age	group	used	for	TaqMan	RT-PCR.	Data	shown	here	represent	mean	±	SEM.		*,	
**,	***	=	p<0.05;	p<0.01	and	p<0.001	respectively,	between	age	comparisons,	one-way	ANOVA	with	
Bonferroni	multiple	comparisons.	
Fig.	2	Changes	in	the	expression	of	endocannabinoid	receptors	CB1,	CB2	and	GPR55	in	the	brainstem	
of	the	rat	during	postnatal	maturation.	 (A)	TaqMan	RT-PCR	analysis	of	CB1	receptor	mRNA	 in	the	
vPAG	of	P10,	P21	and	P40	rats,	no	statistically	significant	changes	were	observed	between	the	ages.	
(B,)	Fluorescent	image	(x20	magnification)	and	quantification	(C)	of	CB1	immunoreactivity	in	the	vPAG.	
White	 arrows	denote	CB1	 specific	 terminal	 staining.	 The	 expression	of	 CB1	 receptors	 in	 the	 vPAG	
decreased	 as	 the	 animals	 aged,	 as	 immunoreactivity	 was	 highest	 at	 P10	 (p<0.0001,	 one-way	
ANOVA).TaqMan	RT-PCR	analysis	of	CB1	receptors	in	the	RVM	of	P10,	P21	and	P40	rats,	no	changes	
were	observed	between	the	ages.	(E)	Fluorescent	image	(x20	magnification)	and	quantification	(C)	of	
CB1	immunoreactivity	in	the	RVM.	White	arrows	denote	CB1	specific	terminal	staining.	The	expression	
of	CB1	 receptors	 in	 the	RVM	 increased	as	 the	animals	aged	 (p<0.01-0.001,	one-way	ANOVA)	 (C,	D	
))N=3-5	animals	per	age	group.	Data	shown	here	represent	mean	±	SEM.		*,	**,	***,	****	=	p<0.05;	
p<0.01;	 p<0.001	 and	 p<0.0001	 respectively,	 between	 age	 comparisons,	 one-way	 ANOVA	 with	
Bonferroni	multiple	comparisons.	
Fig	3.No	changes	in	CB2	transcript	levels	in	the	PAG	and	RVM	whilst	expression	of	the	GPR55	gene	
is	developmentally	regulated.	(A,	B)	TaqMan	RT-PCR	analysis	oCB2	receptor	mRNA	in	the	PAG	and	
RVM	respectively,	no	significant	changes	in	were	detected.	(C,	D)	TaqMan	RT-PCR	analysis	of	GPR55	
receptor	mRNA	 in	the	PAG	and	the	RVM	of	P10,	P21	and	P40	rats	 (p<0.001,	one	way	ANOVA).	No	
changes	were	observed	in	the	PAG	but	GPR55	mRNA	was	transiently	upregulated	at	P21	in	the	RVM	
(D).	N=3-5	animals	per	age	group.	Data	shown	here	represent	mean	±	SEM.		**	=p<0.01,	between	age	
comparisons,	one-way	ANOVA	with	Bonferroni	multiple	comparisons.	
Fig.4	 Changes	 in	 the	 expression	 of	 endocannabinoid	 receptors	 CB1	 and	 CB2	 in	 human	midbrain	
during	 postnatal	maturation.	 (A,	 B)	 TaqMan	 RT-PCR	 analysis	 of	 CB1	 and	 CB2	 receptor	mRNA,	 no	
significant	 changes	 in	 were	 detected.	 (C)	 In	 situ	 hybridisation	 images	 (x20	 magnification)	 of	 CB1	
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receptors	 in	 pre-term,	 term,	 infant	 and	 P40	midbrain.	 (D)	Quantification	 by	 cell	 counting	 analysis	
showed	that	the	expression	of	CB1	receptors	is	higher	during	early	postnatal	development	compared	
to	P40	(p<0.01;	one-way	ANOVA).	(E)	In	situ	hybridisation	images	of	CB2	receptors.	(F)	No	significant	
changes	in	expression	of	CB2	receptors	were	observed	throughout	postnatal	development.	4-8	human	
midbrain	tissue	per	age	group	was	used	for	TaqMan	RT-PCR	and	in	situ	hybridisation	respectively.	Data	
shown	here	represent	mean	±SEM.	*,	**	=	p<0.05	and	p<0.01	respectively,	between	age	comparison,	
one-way	ANOVA	with	Bonferroni	multiple	comparisons	
Fig.	5	Effect	of	intra-PAG	and	RVM	microinjection	of	HU210	(CB1/2	receptor	agonist,	4μg/animal)	
on	withdrawal	reflexes	to	mechanical	vFh	stimulation	in	P10,	P21	and	P40	rats.	(A)	Intra-PAG	HU210	
significantly	 decreased	 spinal	 reflex	 excitability	 compared	 to	 vehicle	 responses	 in	 all	 ages	 tested	
(p<0.0001,	two-way	ANOVA).	This	effect	was	more	pronounced	in	P10	animals	compared	to	P40s.	(B)	
Intra-PAG	HU210	significantly	increased	mechanical	thresholds	in	P21	and	P40	rats	(p<0.0001,	two-
way	ANOVA).	This	effect	is	more	pronounced	in	P21	and	P40	animals	compared	to	P10.	(C)	IntraRVM	
HU210	 decreased	 spinal	 reflex	 excitabilities	 compared	 to	 vehicle	 responses	 in	 all	 ages	 tested	
(p<0.0001,	 two-way	 ANOVA).	 This	 effect	 was	 strongest	 in	 P21	 animals.	 (D)	 Intra-RVM	 HU210	
significantly	 increased	 mechanical	 thresholds	 compared	 to	 vehicle	 responses	 in	 all	 ages	 tested	
(P<0.0001,	two-way	ANOVA).	This	effect	was	strongest	for	P21	animals.	4-8	animals	per	drug	per	age	
group.	Data	shown	here	represent	the	mean	±	SEM.	****	=	p<0.0001,	between	drug	comparisons,	
two-way	ANOVA	with	Bonferroni	multiple	comparisons.	#,	####	=	p<0.05	and	p<0.0001	respectively,	
between	age	comparison,	two-way	ANOVA	with	Bonferroni	multiple	comparisons.		
Fig.	6	Effect	of	intra-PAG	and	RVM	microinjection	of	AM251	(CB1	receptor	inverse	agonist,	GPR55	
receptor	agonist,	2.77	and	1.35μg/animal)	and	LPI	 (endogenous	GPR55	agonist,	12μg/animal)	on	
withdrawal	reflexes	to	mechanical	vFh	stimulation	in	P10,	P21	and	P40	rats.	(A)	Intra-PAG	AM251	
and	LPI	only	decreased	spinal	reflex	excitability	in	P10	and	P21	rats	(p<0.0001,	two-way	ANOVA).	There	
are	significant	age-related	differences	in	AM251	and	LPI	responses	between	P40	and	younger	animals	
(p<0.0001,	two-way	ANOVA).	(B)	Intra-PAG	AM251	and	LPI	did	not	change	the	mechanical	thresholds	
in	 either	P10	or	 P40	 rats,	 but	 significantly	 increased	 it	 in	P21	animals.	 There	 are	 significantly	 age-
related	 differences	 in	 AM251	 and	 LPI	 mediated	 changes	 in	 mechanical	 withdrawal	 thresholds	
(p<0.001,	two-way	ANOVA).	(C)	Intra-RVM	AM251	did	not	have	an	effect	in	P40	rats,	but	significantly	
reduced	spinal	reflex	excitabilities	 in	P10	and	P21	animals.	LPI	 increased	spinal	reflex	excitability	 in	
P40	 rats,	 but	 decreased	 it	 in	 P10	 and	 P21	 animals.	 These	 age-related	 differences	were	 significant	
(p<0.0001,	 two-way	 ANOVA).	 (D)	 Intra-RVM	 AM251	 and	 LPI	 significantly	 increased	 mechanical	
threshold	 in	 P10	 and	 P21	 rats,	 but	 had	 no	 effect	 in	 P40	 animals.	 This	 age-related	 difference	was	
significant	(p<0.0001,	two-way	ANOVA).	(E)	Intra-PAG	AM251	(2.77	and	1.35μg)	did	not	have	an	effect	
in	P40,	but	significantly	inhibited	spinal	reflex	excitability	in	P21	animals	(p<0.0001,	one-way	ANOVA).	
Co-administration	 of	 AM251	 (1.35μg)	 with	 the	 GPR55	 receptor	 specific	 antagonist	 ML193	 (1μg)	
reversed	 AM251-mediated	 inhibition	 of	 spinal	 reflex	 excitability	 in	 P21	 animals.	 	 **,	 ***,	 ****	 =	
p<0.01,	p<0.001	and	p<0.0001	respectively,	between	drug	comparisons,	two-way	ANOVA	and	one-
way	ANOVA	with	Bonferroni	multiple	comparisons.	###.	####	=	p<0.001	and	p<0.0001	respectively,	
between	 age	 comparison,	 two-way	 ANOVA	 and	 one-way	 ANOVA	 with	 Bonferroni	 multiple	
comparisons.	
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